Biomarker testing study for Friedreich’s ataxia
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at “biomarkers” (measurable signs in the body, like test results from blood or other checks) in people with Friedreich’s ataxia. It may help researchers understand the disease better and track changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a genetic diagnosis of Friedreich’s ataxia, or you are a healthy person without a neuromuscular (movement/nerve) disorder
- You are between 6 and 70 years old
- You can safely do metabolic exercise testing
- If you take heart medicines, your dose and regimen have been stable for at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses heart tests (including ultrasound and MRI) to better understand how Friedreich’s ataxia affects the heart. You might benefit by getting detailed heart evaluation and contributing to research that could guide future care.
This study looks at two brain chemicals (GABA and glutathione) in children and teens aged 8–15 with Friedreich's ataxia, a rare genetic condition affecting movement and coordination. The research aims to understand how these chemicals change in the brain and may help guide future treatments.
This study uses an EEG (a painless test that records your brain's electrical activity) to map the brain connections in people with Friedreich's ataxia. It aims to better understand how the condition affects the brain.
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
This study looks at how heart function relates to tiredness in people with Friedreich's Ataxia. You'll ride a stationary bike to measure your heart's output and your fatigue levels.
This trial tests a one-time gene therapy called LX2006 for heart problems caused by Friedreich ataxia. The goal is to see if it can improve heart function and structure.
Hear when a new Friedreich's Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.